VKTX Viking Therapeutics Inc

$VKTX BREAKING: retatrutide just crushed Ozempic head to head. 20.9% weight loss vs 9.4%, in an 80-week phase 3. NVO really needs to decide if they want to be in this market.

$VKTX Partnership has long been the desired arrangement. GIA is the negotiating tool, In my humble opinion.

$VKTX “These results demonstrated an impressive maintenance effect, excellent tolerability, and serve to further establish VK2735 as a differentiated potential treatment option for patients with obesity”-VK PR

$VKTX Luv how BL side-stepped the commercialization preparation question by saying that SG&A spend will be flat for the foreseeable Qs: That means He has no intention of GIA. A BP acquirer will bring its own sales & marketing muscle to the deal. 😉☘️💎 But he did emphasize hiring in Technical Operations. Why? Cuz that's what's needed (CMC, PD, Clinical, Quality, Regulatory Affairs 👍) to get VK2735 SC + PO and VK3019 fully developed to the point that BPs will be trying to outbid each other. Just a sly ribbing directed to our resident arm-chair CEOs on ST. 🤣

$VKTX So many stupid trolls jumping in here again with first time posts and idiotic questions. Exhausting.

$VKTX Controlled accumulation continues. Retail longs are baited to frustration and silly impatience. I see great things over the next 3-5 years. If your patience is limited to the next 3-5 months, shop elsewhere.

$VKTX Piles of cash … Trillion dollar market … full speed ahead There will be competitors coming in Onesity. Lilly & Novo will not be the only games in town! it’s happened in every product category in the past. Here are examples: Statins: Lipitor Crestor Zocor Pravachol et al Blood thinners: Eliquis Xeralto Pradaxa Savaysa et al Ed Drugs: Viagra Cialis Levitra Stendra et al Psoriasis: Skyrizi; Cosentyx; Stelara; Tremfya; Bimzelx; Otezla et al This too will o,e to pass! #SKOL

$VKTX Bl is a disaster. 21/2 years to launch. Purchasing a priority review pass could cut the time to 11/2 years..but BL has no need to rush he will milk the company it as long as possible. VKTX needs a new CEO and/ or a hostile takeover.

$VKTX — STILL BULLISH! 🚀 Today’s earnings don’t change my long-term thesis. VK2735 continues to advance in Phase 3, with both injectable trials fully enrolled and the oral Phase 3 program now underway. Viking also has about $960M in cash to keep pushing its pipeline forward. At $25, I’m adding. I see a lot of potential over the next 2–5 years. ⚠️ High risk, but potentially high reward. If you like risk, this could be an interesting opportunity. If not, stay away. I’m staying patient and bullish. 👊

$VKTX $3B market cap lmfao. Gotta be the biggest disconnect in biotech rn. Oh 🐳 the longer it sits around here the more I can accumulate

$VKTX I hope folks are prepared for this long haul. Buckle up because we have at least another 10-12 months of this. You can complain about the SP, BL bash, whatever it takes to sooth your frustration. But get comfy, because it’s going to be a longer, more stressful ride than you were expecting.

$VKTX ER Call Odds 90% chance of business as usual, with a dollop of BLshit on the side 7% chance of not so bad 2% chance of partnership 1% chance of BL stepping aside (AFT, buy that news)

$VKTX The violation of $24.75 and the test of $24.02 occurred without institutional block dumping. Rather than broad distribution, the move below $24.75 is the result of a thinned order book where market makers lowered bids to sweep lingering retail stop-losses. Protect your shares...

$VKTX CEO commented on DC rate in the vanquish phase 3 as per expectations in response to an analyst question . I can say there is no problem with DC rate as I hear from multiple sources . his expectations are probably positive and thus asking for dozens of billions as leaking for a price ? But BL as non obesity clinician can’t feed on opportunities.. as when asked on his opinion on $LLY TZP + Elora combo. He responded as being impressed by efficacy but couldn’t comment on tolerability .. I would have said a single highly effective unimolecular GLP1-GIP peptide - Vk2735 can give u excellent wt loss for > 80% of pts , with low DC rate and with no need to struggle with tolerability of combining GLP1 class with amylin class, at least from fatigue if not from GI etc. as seen in high DC rate in Lilly combo even in diabetics who tolerate better but BL wants to combine with VK amylin. Although I beleive among all GLP1 - amylin combos u will not see more than 10% of pts

$VKTX BL is a brilliant scientist. No doubt about that, and there’s no question that this is what interests him. But at this point, a CMO role alongside a position on the board would be more appropriate. There’s simply no way we should have to put up with a CEO on that kind of salary and compensation package who manages to talk the stock down by 5% every single fucking time he opens his mouth, while saying absolutely nothing.

$VKTX Update -- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated -- -- Phase 1 SAD Study of Amylin Agonist VK3019 Nearing Completion -- -- Strong Quarter-End Cash Position of $960 Million --

$VKTX VKTX stock price in September, 2018 hit $24/share. In the over 8 years since that time, the stock price is up 3 cents. Since that time, clinical trials have shown that VKTX has a MASH drug sitting on the shelf after P2 that actually appears to be better than the leading MASH drug Rezdiffra. VKTX has an obesity drug late in P3 that appears to be better than the world's best-selling drug. Yet VKTX is up three cents in eight years, in spite of tremendous clinical results and having drugs that look like world-beaters. Maybe it's time for new leadership?

$VKTX Historically we drop 3-5% if BL opens his mouth, the only thing he could say today on the CC is a serious willingness to partner, if he says GIA they gonna kill us! GL

$VKTX - most of these CEO bashers here are working for BP(s) which are trying to manipulate SP and changing narrative against CEO to put him under pressure to force him and accept low valueation offer based on current SP + standard premium. And BL is not giving up to those BP's pressure, and continuing to execute on development front. I hope he make partnership deal for MASH candidate soon which will bring more cash and proceed that asset in late stage development. Very

$VKTX hopefully Brian gives us a clue or a small hint about Viking's positive future tomorrow and we turn this ship around for good